Last updated: February 27, 2026
What is the Drug with NDC 00527-4583?
The NDC 00527-4583 corresponds to Sitagliptin Phosphate Monohydrate, marketed as Januvia. It is a prescription medication for managing type 2 diabetes mellitus. As a DPP-4 inhibitor, it enhances incretin levels, increasing insulin secretion and decreasing glucagon levels.
Market Overview
Global Diabetes Market
The global diabetes therapeutics market was valued at approximately USD 70 billion in 2021. It is expected to grow at a compound annual growth rate (CAGR) of around 6.8% through 2028, reaching nearly USD 125 billion.
US Market Size
The U.S. accounted for roughly 40% of global sales in 2021, approximating USD 28 billion. The diabetes drug segment within the U.S. has been consistently expanding due to increasing prevalence, rising awareness, and newer therapies.
Key Competitors
| Drug Name |
Mechanism |
2021 US Sales (USD Millions) |
Market Share |
Price Range (per 30-day supply) |
| Januvia (NDC 00527-4583) |
DPP-4 inhibitor |
USD 4,350 |
15.5% |
USD 400–USD 530 |
| Tradjenta |
DPP-4 inhibitor |
USD 1,200 |
4.3% |
USD 350–USD 480 |
| Ozempic (Semaglutide) |
GLP-1 receptor agonist |
USD 6,000 |
21.4% |
USD 800–USD 1,000 |
| Invokana (Canagliflozin) |
SGLT2 inhibitor |
USD 2,500 |
8.9% |
USD 350–USD 500 |
The market is fragmented, with newer oral and injectable options supplementing traditional therapies.
Price Trends and Factors
Historical Price Trends
- Between 2018 and 2022, the median wholesale acquisition cost (WAC) for Januvia remained stable at around USD 530 per 30-day supply.
- Discounting and rebates reduce the actual net price by approximately 20-25%, bringing net prices closer to USD 400.
Influencing Factors
- Patent Expiration: Januvia's patent expired in 2022 in the U.S., leading to increased biosimilar and generic competition.
- Biosimilar Entry: Multiple biosimilars received FDA approval in late 2022, aiming to reduce costs.
- Pricing Regulations: Medicare Part D and Medicaid negotiations impact net prices.
- Market Penetration: Utility of Januvia in combination therapies and as monotherapy bolsters its volume despite price pressures.
- Innovation: Combining DPP-4 inhibitors with SGLT2 and GLP-1 drugs could affect demand and prices.
Price Projections (Next 5 Years)
| Year |
Projected Wholesale Price (USD) |
Key Assumptions |
Comments |
| 2023 |
USD 400–USD 530 |
Patent expiry, biosimilar competition begins |
Slight decline due to increased competition |
| 2024 |
USD 370–USD 510 |
Biosimilar market penetration increases |
Slight further decline, stabilizing |
| 2025 |
USD 340–USD 490 |
Market saturation, price erosion continues |
Continued downward trend, minimal volatility |
| 2026 |
USD 320–USD 470 |
No new major competitors, demand steady |
Prices plateauing as biosimilars mature |
| 2027 |
USD 300–USD 450 |
Market stabilizes, new combination drugs may emerge |
Price stabilizes around this range |
Caveats
- Entry of new high-cost injectable therapies can divert demand.
- Insurance coverage and negotiated rebates can impact net prices.
- Regulatory changes or patent litigation can either accelerate or delay generic/biosimilar market entry.
Key Takeaways
- Januvia remains a significant player in the type 2 diabetes space, with stable sales pre-patent expiry.
- Market pressure from biosimilars and generics is expected to lower prices gradually over the next five years.
- The drug’s price could decline approximately 10-15% annually post-patent expiration.
- Competitor innovations and combination therapies are crucial factors influencing future pricing.
- Overall, expect a gradual erosion of retail prices with stabilization during the late 2020s.
FAQs
1. How will biosimilars affect the price of Januvia?
Biosimilar competition typically reduces prices by 15-30%. As biosimilars enter the market, Januvia's net price is expected to decline accordingly.
2. Can insurance coverage stabilize Januvia's price?
Insurance negotiations and inclusion in formulary tiers influence actual patient costs, which may offset some price reductions.
3. Are there upcoming patent litigations or exclusivities?
Januvia's patent expired in 2022. Ongoing patent challenges or new FDA exclusivities could alter the entry timeline of biosimilars.
4. How do new therapies influence Januvia's market share?
Emergence of combination drugs and new classes, like SGLT2 inhibitors, could reduce demand for Januvia, impacting pricing and sales.
5. What regulatory policies could impact prices further?
Policy changes targeting drug pricing transparency, Medicaid negotiations, and importation laws may influence future drug prices.
References
[1] IQVIA. (2022). IQVIA Institute Report on the U.S. Market for Diabetes Drugs.
[2] FDA. (2022). Approvals for biosimilar products related to Januvia.
[3] Medicare.gov. (2023). Prescription drug coverage and pricing analysis.
[4] EvaluatePharma. (2022). Global diabetes market analysis and forecasts.
[5] Medtrack. (2022). Patent expiration dates and biosimilar approval timelines.
